Evidence map›Paper›PMID 42675222›Full record

ArticleOncogene2026

Neuromedin U 'innervation' reprograms myeloid immunosuppression in neuroendocrine prostate cancer.

Michela Perego, Jozef Madzo, Andrew V Kossenkov, F Cansu Atilgan, Marcella Tazzari, Maria Maddalena Tumedei, Francesco Limarzi, Cristian Lolli, Giorgia Gurioli, Alessandro Fatatis and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Michela PeregoProstate Cancer Discovery and Development Group, Philadelphia, PA, USA. mperego@wistar.org.ORCID http://orcid.org/0000-0002-5671-928X
Jozef MadzoBioinformatics Shared Resource, The Wistar Institute, Philadelphia, PA, USA.
Andrew V KossenkovProstate Cancer Discovery and Development Group, Philadelphia, PA, USA.
F Cansu AtilganProstate Cancer Discovery and Development Group, Philadelphia, PA, USA.
Marcella TazzariAdvanced Cellular Therapies and Rare Tumors Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC), Italy.
Maria Maddalena TumedeiAdvanced Cellular Therapies and Rare Tumors Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC), Italy.
Francesco LimarziPathology Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, Italy.
Cristian LolliDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC), Italy.
Giorgia GurioliBiosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC), Italy.
Alessandro FatatisDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-3945-8513
Mary V IacoccaDepartment of Pathology, Helen F. Graham Cancer Center and Research Institute, Christiana Care Health, Newark, DE, USA.
Nicholas J PetrelliDepartment of Pathology, Helen F. Graham Cancer Center and Research Institute, Christiana Care Health, Newark, DE, USA.
Justine J JacobiProstate Cancer Discovery and Development Group, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-9109-3294
David W GoodrichProstate Cancer Discovery and Development Group, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-1021-1827
Lucia R LanguinoProstate Cancer Discovery and Development Group, Philadelphia, PA, USA.
Dario C AltieriProstate Cancer Discovery and Development Group, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-0617-3469

Funding

Prostate Cancer Foundation (PCF) 22CHAL13U.S. Department of Health & Human Services | NIH | Center for Scientific Review (NIH Center for Scientific Review) CA234162U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA298993
6 · The paper itself

Abstract

Neuroendocrine prostate cancer (NEPC) is an increasingly recognized, highly aggressive disease variant with no actionable therapeutic targets and a life expectancy of 7 months or less. Using a transgenic mouse model, we now show that early stages of NEPC are associated with increased intraprostatic recruitment of Ly6G

Identifiers

PMID42675222

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.